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Concise report
B-cell activity markers are associated with different
disease activity domains in primary Sjo¨gren’s
syndrome
Katherine James1,2, Chimwemwe Chipeta3, Antony Parker4, Stephen Harding4,
Simon J. Cockell5, Colin S. Gillespie6, Jennifer Hallinan2,7, Francesca Barone3,
Simon J. Bowman3,8, Wan-Fai Ng1 and Benjamin A. Fisher3,8; for the UK Primary
Sjo¨gren’s Syndrome Registry
Abstract
Objectives. B-cell activating factor (BAFF), b-2 microglobulin (b2M) and serum free light chains (FLCs) are
elevated in primary SS (pSS) and associated with disease activity. We aimed to investigate their associ-
ation with the individual disease activity domains of the EULAR Sjo¨gren’s Syndrome Disease Activity Index
(ESSDAI) in a large well-characterized pSS cohort.
Methods. Sera from pSS patients enrolled in the UK Primary Sjo¨gren’s Syndrome Registry (UKPSSR)
(n= 553) and healthy controls (n= 286) were analysed for FLC (k and ), BAFF and b2 M. Pearson correl-
ation coefficients were calculated for patient clinical characteristics, including salivary flow, Schirmer’s
test, EULAR Sjo¨gren’s Syndrome Patient Reported Index and serum IgG levels. Poisson regression was
performed to identify independent predictors of total ESSDAI and ClinESSDAI (validated ESSDAI minus
the biological domain) scores and their domains.
Results. Levels of BAFF, b2M and FLCs were higher in pSS patients compared to controls. All three
biomarkers associated significantly with the ESSDAI and the ClinESSDAI. BAFF associated with the
peripheral nervous system domain of the ESSDAI, whereas b2M and FLCs associated with the cutaneous,
biological and renal domains. Multivariate analysis showed BAFF, b2M and their interaction to be
independent predictors of ESSDAI/ClinESSDAI. FLCs were also shown to associate with the ESSDAI/
ClinESSDAI but not independent of serum IgG.
Conclusion. All biomarkers were associated with total ESSDAI scores but with differing domain associ-
ations. These findings should encourage further investigation of these biomarkers in longitudinal studies
and against other disease activity measures.
Key words: Sjo¨gren’s syndrome, B cells, B-cell activating factor, b-2 microglobulin, free light chains, disease
activity, biomarker
Rheumatology key messages
. B-cell activity markers correlate with systemic disease activity in primary Sjo¨gren’s syndrome.
. Different B-cell activity biomarkers had differing systemic disease domain associations in primary Sjo¨gren’s syndrome.
. The role of these biomarkers should be further established in longitudinal studies in primary Sjo¨gren’s syndrome.
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Introduction
Primary SS (pSS) is characterized by autoimmune
inflammation of exocrine glands resulting in severe dry-
ness. B-cell hyperactivity has been implicated in the
pathogenesis and may contribute to the development of
systemic manifestations [1, 2]. Systemic manifestations
vary between patients and it is unclear how this hetero-
geneity is reflected in the underlying pathogenesis.
The EULAR Sjo¨gren’s Syndrome Disease Activity Index
(ESSDAI), was introduced with the aim of providing
clinicians with a way of objectively measuring disease
activity in pSS [3]. The ESSDAI is comprised of 12 disease
activity domains, and is now the most commonly used
primary outcome measure in pSS clinical trials. In order
to avoid confounding in biomarker studies the ClinESSDAI
was developed, in which the biological domain has been
removed [4]. However, the ESSDAI has other limitations,
such as its dependence on physician assessment, the
difficulty of accurately assessing change in some do-
mains, and the heavy skewing of the population towards
low scores [5]. Therefore, there is interest in developing
biomarkers of disease activity such as histopathology
[6, 7], US [8, 9] and serum measures of B-cell activity.
Proposed B-cell biomarkers include B-cell activating
factor (BAFF) [10], b-2 micgroglobulin (b2M) [11, 12]
and immunoglobulin free light chains (FLCs) [11]. BAFF
promotes the survival and proliferation of B cells
and mice overexpressing BAFF develop Sjo¨gren’s-like
features [2].
b2M forms part of the HLA class 1 molecule and enters
the serum when it is shed from the cell membrane. It can
be used as a marker for disease activity in conditions with
high cell turnover and may act as a non-specific marker of
plasma cell activity.
During immunoglobulin (Ig) synthesis, light chains are
produced in excess of heavy chains. These excess light
chains are secreted and are a marker of plasma cell
activity [13]. FLC levels are elevated in pSS patients
compared with controls and have been linked to total
disease activity [11]. FLCs have a half-life of 26 h,
making them a more dynamic marker of plasma cell
activity in comparison with IgG [13].
While many studies have investigated potential bio-
markers using the ESSDAI as the dependent variable,
few studies have investigated a link between biomarkers
and individual disease activity domains. Understanding
the association of biomarkers with specific disease activ-
ity domains is important, firstly, to provide insight into
the pathogenesis of the differing extra glandular manifest-
ations, and, secondly, to avoid confounding through
the expected association of B-cell activity biomarkers
with the ESSDAI biological domain or through other
domain-specific effects. Therefore, this study aims to
investigate the relationship between the B-cell activity
biomarkers BAFF, b2M and FLCs with disease activity
in a large clinically well-characterized pSS cohort [5]
using the ESSDAI and ClinESSDAI and their individual
domains.
Methods
Patient recruitment and serum analysis
Serum samples for 553 pSS patients and 286 healthy
controls were retrieved from the UK primary Sjo¨gren’s
syndrome registry (UKPSSR) Biobank; representing all
UKPSSR subjects with available sample at the time of
testing. All patients fulfilled 2002 American European
Consensus Group classification criteria.
Healthy controls were recruited via two routes. First,
participants were asked to voluntarily bring one to three
friends of the same gender and similar age but without SS.
Second, advertisements were placed at the recruiting
centres. All healthy volunteers were asked to complete a
general health questionnaire to screen for the presence of
any significant autoimmune conditions. Only those sub-
jects with no self-reported autoimmune conditions were
included. Ethics committee approval was granted by the
North West Haydock Research Ethics Committee and all
subjects gave written informed consent in compliance
with the Declaration of Helsinki.
Samples were analysed for serum FLCk and FLC and
b2M on the SPAPLUS turbidimeter (The Binding Site
Group, Birmingham, UK). Combined FLC concentrations
were determined by summating the individual FLCk and
FLC results (FLC). BAFF was measured using a com-
mercially available enzyme immunoassay (Quantikine,
R&D Systems, Abingdon, UK) following the manufac-
turer’s instructions (serum reference inter-
val = 5841186 pg/ml, according to product insert).
Data analysis
Assay data were log transformed and scaled prior to stat-
istical analysis. Pearson correlation coefficients were
calculated for patient characteristics and serum levels.
Statistically significant r values of 0.100.29 were con-
sidered to be a weak association, 0.300.49 moderate
and 0.501.0 strong. Poisson regression was performed
to determine predictors for ESSDAI and ClinESSDAI and
their subdomains, as the outcomes were discrete, with
activity scores in some domains being mutually independ-
ent. A P < 0.05 was considered significant (after adjust-
ment using the Benjamini-Hochberg false discovery rate
where necessary). Analyses were performed using the
R environment for statistical computing.
Results
Patient characteristics and serum biomarker levels
Five hundred and fifty-three pSS patients and 286 healthy
controls were analysed. Most patients and controls were
female (95.1% vs 90.9%) and of Caucasian ethnicity
(93.7% vs 88.1%). However, mean age was higher in
the pSS group (59.1 years; ±12.3) compared with controls
(48.0 years; ±11.12).
Levels of BAFF, b2M and FLCs were higher in pSS
patients compared with controls (supplementary Fig. S1,
available at Rheumatology online).
P
FLC strongly corre-
lated with b2M (r= 0.75, P < 0.001) but only weakly with
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BAFF (r= 0.11, P < 0.001). BAFF and b2M showed a mod-
erate correlation (r= 0.39, P < 0.001).
Abnormal k/ FLC ratios were found in 101 (18.3%) pSS
patients and 25 (8.7%) controls. All abnormal k/ FLC
ratios were due to disproportionally high FLCk levels. A
comparison of pSS subjects with and without an abnormal
k/ FLC ratio is shown in supplementary Table S1, avail-
able at Rheumatology online. The abnormal ratio pSS
patients had a marginally higher rate of anti-Ro/La +ve
antibodies when compared with the normal ratio pSS pa-
tients (94.1% vs 89.2%). The median ESSDAI score of
abnormal ratio patients was similar to that of normal
ratio patients (4.0 vs 3.0; P = 0.27); likewise with
ClinESSDAI (4.0 vs 3.0; P = 0.38). However, subjects
with an abnormal ratio had a higher prevalence of activity
in the biological (69.3% vs 46.5%, P < 0.001) and renal
domains (6.93% vs 2.2%; P = 0.02) although numbers in
the latter domain were small. Abnormal ratio patients were
also more likely to have both anti-Ro and anti-La antibo-
dies (81.2% vs 70.6%, P = 0.04). Although an abnormal
k/ FLC ratio suggestive of clonality could be scored as
low disease activity on the biological domain [14], all scor-
ing was undertaken without knowledge of FLC values.
However, only 12 out of 88 (13.6%) patients in the abnor-
mal ratio group who had serum electrophoresis data avail-
able had a monoclonal band, and 31/101 (30.7%) patients
in the group were scored as no activity on the biological
domain. All subsequent analyses included pSS subjects
with an abnormal k/ FLC ratio, although excluding them
did not substantially change our findings (data not shown).
Serum biomarkers and clinical features
Correlation of serum biomarkers and age, disease duration,
symptom duration, average Schirmer’s test, unstimulated
salivary flow rate, complement C3 and C4 levels and
serum IgG are shown in supplementary Table S2, available
at Rheumatology online. FLCs showed a moderate correl-
ation with serum IgG levels. FLCk and FLC had a
weak but statistically significant inverse correlation with
C4 levels. FLCs did not correlate with other clinical
features. BAFF had a weak but significant correlation with
disease duration (r= 0.11, P < 0.01) and symptom duration
(r= 0.14, P < 0.001), and a weak inverse correlation with
average Schirmer’s (r = 0.11, P < 0.05). b2M correlated
weakly with age (r= 0.20, P < 0.001) and IgG levels
(r= 0.21, P < 0.001), and had a weak inverse correlation
with average Schirmer’s (r = 0.11, P < 0.01).
Biomarker relationship with the ESSDAI and
its domains
Complete data for ESSDAI and IgG levels were available for
539 pSS subjects. All exploratory biomarkers were found to
have a statistically significant positive association with both
total ESSDAI and ClinESSDAI scores (P < 0.001 for all)
(supplementary Table S3, available at Rheumatology online).
Table 1 shows the results of Poisson regression of
serum biomarkers against the ESSDAI domains. BAFF
showed a statistically significant association with the
peripheral nervous system (PNS) domain (P < 0.001),
but not with any other domain. b2M and FLCs were sig-
nificantly associated with the cutaneous, biological and
renal domains (P < 0.001 for all). Figure 1 shows the
level of serum biomarkers in relation to the activity levels
of their associated domains (biological domain excluded).
The association of FLC and b2M with the total ESSDAI
score remained after correction for estimated glomerular
filtration rate (eGFR), (supplementary Table S3, available
at Rheumatology online). Furthermore, both FLC and b2M
remain associated with the renal domain after correction
for eGFR (data not shown).
Multivariate ESSDAI
On multivariate analysis of serum biomarkers against the
total ESSDAI (supplementary Table S4, available at
Rheumatology online), BAFF and b2M were found to be in-
dependent predictors of the ESSDAI. They were also found
to have an interaction. FLCs offered no additional value to
measured IgG on multivariate regression. Broadly similar
results were seen in multivariate analysis of biomarkers in
relation to total ClinESSDAI scores. b2M,
P
FLC and the
TABLE 1 Poisson regression P-values for association of biomarkers with individual ESSDAI domains
ESSDAI domain BAFF b2M FLCj FLCi DFLC IgG
Constitutional 2.93E-01 2.13E-01 2.93E-01 2.13E-01 2.13E-01 2.13E-01
Lymphadenopathy 6.71E-01 6.71E-01 6.29E-01 1.94E-01 1.94E-01 7.80E-01
Glandular 8.35E-01 4.35E-01 3.91E-01 1.74E-01 1.74E-01 1.74E-01
Articular 4.03E-01 7.73E-01 4.03E-01 4.03E-01 4.03E-01 9.14E-02
Cutaneous 2.15E-01 6.90E-04*** 1.14E-03*** 9.56E-06*** 4.21E-05*** 4.93E-03**
Respiratory 1.62E-01 1.62E-01 9.33E-01 9.33E-01 9.33E-01 3.07E-01
Muscular 3.01E-01 7.99E-02 7.06E-01 3.01E-01 3.53E-01 4.14E-01
Peripheral nervous system 2.25E-05*** 5.22E-02 8.90E-01 8.90E-01 8.90E-01 8.90E-01
Haematological 1.73E-01 1.73E-01 5.91E-01 4.28E-01 4.50E-01 5.91E-01
Biological 5.97E-01 2.94E-15*** 5.03E-29*** 1.32E-35*** 9.84E-36*** 2.00E-49***
Renal 1.57E-01 3.71E-16*** 1.43E-09*** 1.01E-10*** 8.38E-11*** 7.07E-02
CNS domain excluded since only two patients active. **P<0.01. ***P<0.001. BAFF: B cell activating factor; b2M: b-2 micro-
globulin; FLC: free light chain.
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interaction of BAFF and b2M were all found to be independ-
ent predictors within the same model. However, the overall
ability of these models to explain variation in actual ESSDAI
or CLinESSDAI scores was small.
Discussion
Serum FLCs, BAFF and b2M levels all showed statistically
significant associations with total ESSDAI/ClinESSDAI
scores, with BAFF and b2M showing both independent
and multiplicative associations on multivariate testing.
BAFF was significantly associated with the PNS and no
other domains whereas b2M and all FLCs were significantly
associated with the cutaneous, biological, and renal do-
mains. These differing associations are consistent with
there being only weak to moderate correlation of FLCs and
b2M with BAFF levels, and indicate that these biomarkers
provide complementary and non-redundant information.
Previous studies have reported an association of FLCs
and b2M with the total ESSDAI score [11, 12, 15], but did
not explore relationships with the individual domains. The
relationship between serum BAFF and ESSDAI domains has
FIG. 1 Relationship of serum biomarkers with activity levels of their associated domains (biological domain excluded)
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been explored in two small studies [10, 16]. BAFF was asso-
ciated with lymphadenopathy, glandular and pulmonary do-
mains in a cohort of 58 patients [10], while in another study
of 76 patients BAFF was associated with the constitutional,
lymphadenopathy, glandular, and biological domains [16].
The latter study included a high proportion of pSS patients
with lymphoproliferative disorders. These findings are in
contrast to our much larger study in which BAFF only
showed an association with the PNS domain. There are di-
verse manifestations of PNS involvement in pSS with both
vasculitic and non-vasculitic neuropathies. However, BAFF
is elevated in non-pSS patients with chronic inflammatory
demyelinating polyneuropathy [17, 18] and is also ex-
pressed by perivascular and intramural lymphocytes in pa-
tients with non-systemic vasculitic neuropathy [19].
FLCs are excreted by the kidneys and b2M is freely filtered
by the glomeruli and reabsorbed into the proximal renal tu-
bules, where it is then degraded. Thus, renal impairment can
increase serum FLCs and b2M. However, the association of
these biomarkers with the renal domain remained following
correction for eGFR, suggesting that this association is not
an artefact introduced by renal impairment. The commonest
manifestation of renal involvement in pSS is distal renal tubu-
lar acidosis due to tubulointerstitial nephritis in which infiltra-
tion of B cells and plasma cells is common [20].
Close to 20% of pSS patients were found to have an
abnormal k/ ratio, all due to elevated kFLCs. We hy-
pothesize that these abnormal ratios reflect the favouring
of k light chain usage by dominant public clonotypes of
pSS-related autoantibodies [21].
In this study, we used ESSDAI as the gold standard for
assessing disease activity. While the ESSDAI is a useful tool,
it does have some limitations, and does not assess glandular
activity unaccompanied by palpable swelling. Given these
limitations, the inability of our multiparameter models to ac-
curately predict ESSDAI scores does not negate the poten-
tial value of these biomarkers. While we could not identify an
independent predictive value of FLCs over the more com-
monly measured IgG levels, the cross-sectional nature of our
study means we cannot exclude their utility in longitudinal
cohorts or interventional trials. The considerably shorter half-
life of FLCs in comparison to IgG could allow more dynamic
monitoring of B-cell hyperactivity in such settings. A key
strength of our study is it being the largest to date, giving
it the ability to assess the relationship of these B-cell bio-
markers with ESSDAI domains. However, larger numbers
still would be required for some of the domains where dis-
ease activity is rare, such as the CNS and muscular.
Furthermore, the clinical significance of our findings is
unclear, given the relatively weak associations observed.
In conclusion, all three biomarkers were shown to
associate significantly with total ESSDAI scores but with
differing domain associations. Further investigation of
these biomarkers is warranted.
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